EMEA-002113-PIP01-16-M01
Key facts
| Active substance |
(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride (KH176)
|
| Therapeutic area |
Other
|
| Decision number |
P/0149/2022
|
| PIP number |
EMEA-002113-PIP01-16-M01
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of mitochondrial respiratory chain/oxidative phosphorylation defects
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Khondrion BV
Email: info@khondrion.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|